#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Ceftaroline vs. Vancomycin in the Treatment of Acute Pulmonary Exacerbation of Cystic Fibrosis

Up to 25% of patients with cystic fibrosis are colonized with methicillin-resistant Staphylococcus aureus (MRSA). The first-line drug for acute pulmonary exacerbation is vancomycin. The study presented below examined the efficacy and safety of an alternative treatment with ceftaroline (a 5th generation cephalosporin) for this indication.
Source: Anti-Infectives 22. 4. 2022

News Efficacy and Safety of Fixed Combination of Olopatadine and Mometasone in Nasal Spray for Treatment of Seasonal Allergic Rhinitis

Patients with allergic rhinitis require medications with rapid onset and long duration of action. The combination of intranasal antihistamines and corticosteroids has proven effective in the past. The efficacy and safety of a fixed combination of olopatadine and mometasone in a nasal spray (GSP301) was evaluated in the study presented below by a team of American authors.
Source: Life Without Allergic Rhinitis 27. 4. 2022

News Efficacy and Safety of Bimekizumab in the Treatment of Moderate to Severe Plaque Psoriasis -⁠ BE READY Study Results

The interleukin 17 (IL-17) family represents a group of pro-inflammatory cytokines that play a crucial role in the pathogenesis of psoriasis. Inhibiting interleukins from this family has a significant anti-inflammatory effect and represents a promising therapeutic target for newly developed and applied drugs.
Source: Psoriasis 6. 5. 2022

News Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin

Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2 diabetes (T2D). Reducing the incidence of macrovascular CV events in diabetics requires more than just glycemic control alongside all other present CV risk factors. New antidiabetic drugs represent a very promising group of medications with a favorable safety profile, aiding in reducing the risk of CV complications.
Source: Diabetes 19. 4. 2022

News Is it possible to extend the life of diabetics thanks to modern treatment?

People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared to their peers without a diabetes diagnosis. However, clinical study results suggest that modern therapy can prevent these lost years.
Source: Diabetes 29. 4. 2022

News Empagliflozin Secures Reimbursement for Heart Failure Treatment

Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for patients with heart failure with reduced ejection fraction. Cardiologists, pediatric cardiologists, angiologists, and internists will be able to prescribe it with reimbursement. This decision was made by the State Institute for Drug Control (SÚKL) in mid-April. Hundreds of thousands of Czechs suffering from this serious condition will now have access to another effective medication. The drug is manufactured by Boehringer Ingelheim.
Source: Heart Failure 3. 5. 2022

News Gut-Brain Axis −⁠ Future of MS Treatment?

The relationship between the gut microbiome and multiple sclerosis has been a major topic recently. How far has current science progressed in decoding this issue? A recent review article published in the journal Neuroscience Research summarizes the existing findings on the relationship of the gut microbiome to the etiopathogenesis and course of multiple sclerosis (MS).
Source: Multiple Sclerosis 3. 5. 2022

News Teriflunomide under the microscope in studies and practice

Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and individual studies?
Source: Multiple Sclerosis 3. 5. 2022

News Effectiveness of Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Clinical Practice

One of the new modalities for the treatment of ulcerative colitis (UC) is tofacitinib. Its effectiveness has already been demonstrated in clinical studies and is now being proven in real-world clinical practice, where we can evaluate the results of patients who could not be included in clinical trials or those with refractory disease.
Source: Intestinal Inflammations 24. 11. 2022

News Current View on the Issue of Protein Intake in Critically Ill Patients

A summary of current knowledge and guidelines concerning the nutritional needs of critically ill patients presented last year in the journal Clinical Nutrition deals with protein intake, specifically its optimal amount, risks of incorrect approaches to protein administration, and methods for assessing the nutritional status of patients in intensive care units.
Source: Parenteral Nutrition 5. 5. 2022

News Reduction of Mortality in Patients After Abdominal Surgery in Critical Condition Thanks to Early Supplemental Parenteral Nutrition

Ensuring adequate nutrition is an important part of therapy for critically ill patients to achieve better clinical outcomes in terms of both survival and recovery speed. The preferred option is enteral nutrition (EN), which, however, cannot be provided for many reasons to patients after acute abdominal surgery. The results of studies assessing the efficacy of parenteral nutrition (PN) in this specific group of patients are inconsistent. The purpose of the study recently published in Clinical Nutrition was therefore to evaluate the effect of early supplementary parenteral nutrition in critically ill patients after acute abdominal surgery.
Source: Parenteral Nutrition 5. 5. 2022

News Focused on MS: Statistics Are Boring, But They Have Valuable Data!

What is the prevalence of multiple sclerosis? Has the proportion of patients treated with highly effective therapy changed? We bring you the latest data from around the world and domestically.
Source: Multiple Sclerosis 23. 5. 2022

News Epstein-Barr Virus –⁠ Is the Culprit of MS Revealed?

Could the Epstein-Barr virus hold the answer to the etiology of multiple sclerosis? A dataset of over 10 million American recruits offered intriguing insights. You may have encountered the conclusions of one of the most extensive studies in modern history in the media. Let's take a closer look at the work of Kjetil Bjornevik and his colleagues.
Source: Multiple Sclerosis 23. 5. 2022

News Safety and Efficacy of Combination Therapy for Allergic Rhinitis Compared to Monotherapies and Placebo

Combination therapy of antihistamine and corticosteroid is a promising alternative for patients suffering from seasonal allergic rhinitis. A phase II clinical study aimed to determine the effective dosage, efficiency, and safety of combination therapy compared to monotherapies and placebo.
Source: Life Without Allergic Rhinitis 7. 6. 2022

News Allergic Rhinitis in the General Practitioner’s Office: How to Proceed in Primary Care?

Up to 60% of the population has a genetic predisposition to allergic disease. Diagnosis and therapy of allergic conditions are therefore very common topics in primary care. How should we proceed correctly in the diagnostic process when suspecting allergic rhinitis? When to refer to a specialist and what are the treatment options?
Source: Life Without Allergic Rhinitis 7. 6. 2022

1 63 64 65 66 67 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#